Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials

Abstract

The present study aimed to compare the effects of vinorelbine-based neoadjuvant chemotherapy and vinorelbine-free regimens. A meta-analysis of all the relevant randomized controlled trials was performed to investigate the improvement in pathological complete response (pCR), overall response rate (ORR) and breast-conserving surgery (BCS). The PubMed and Embase databases were searched for relevant studies reporting randomized controlled trials comparing vinorelbine-based neoadjuvant chemotherapy with vinorelbine-free regimens until July 2013. Risk ratios/odds ratio and 95% confidence intervals (CIs) were used to estimate the association between vinorelbine in neoadjuvant chemotherapy and various efficacy outcomes. Fixed-or random-effect models were adopted to pool the data. Five eligible studies with a total of 1,495 patients were included in the meta-analysis. Compared to vinorelbine-free chemotherapy, vinorelbine-based regimens demonstrated no significant improvement in clinical outcomes including: pCR [relative risk (RR)=1.016; 95% CI, 0.738-1.399; P=0.922], ORR (RR=1.048; 95% CI, 0.969-1.133; P=0.239) and BCS (RR=1.764; 95% CI, 0.734-4.239; P=0.205). However, vinorelbine-based regimens were associated with a lower incidence of grade 3-4 alopecia (OR, 0.617; 95% CI, 0.448-0.848; P=0.003). In a hierarchical analysis for patients who received neoadjuvant chemotherapy, the proportion of subjects achieving pCR was significantly increased when HER2-amplified (RR=2.31; 95% CI, 1.20-4.43; P=0.01) and hormone receptor negative (RR=0.488; 95% CI, 0.263-0.908; P=0.023). The present review confirms that neoadjuvant chemotherapy vinorelbine-based regimens are unlikely to emerge as superior to pCR, ORR and BCS. Hierarchical analysis indicated that the HER2-amplified and hormone receptor-negative patients were significantly associated with a pathological response rate.

Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma

“…Vinorelbine is a semisynthetic vinca-alkaloid and is often used as a microtubule destabilizing agent [12]. It suppresses tumor cell karyomitosis which in turn disrupts mitotic spindle formation and prevents cell division by inhibiting the polymerization of microtubules [13]. In addition, related studies had shown that the vinca-alkaloid had the potential to inhibit tumor metastasis [14].…”

The effectiveness of multiflora honey to prevent hepatotoxicity in invasive ductal breast cancer patients with FAC chemotherapy

“…Free radicals from these byproducts are toxic for cancer cells and healthy body cells, especially actively dividing cells. 15 A previous study has been directed to use the potential of natural ingredients as agents to reduce side effects such as hepatotoxicity. 16 One of the natural ingredients that have the potential to reduce hepatotoxic effects is honey.…”

“…18 Free radicals of these byproducts are toxic to the cancer cell and healthy body cells, especially actively dividing cells. 15 Phenolic acids and…”